Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-01367338

Known as: PARP1 Inhibitor PF-01367338 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Purposepoly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
Is this relevant?
2013
2013
Poly (ADP-ribose) polymerase (PARP) inhibitors are an emerging class of potential anti-cancer therapeutics currently being… Expand
Is this relevant?
2011
2011
e13576 Background: PARP is a key enzyme involved in base-excision repair. Pre-clinically it has been shown that BRCA1/2 deficient… Expand
Is this relevant?
2011
2011
3104 Background: AG-014699 (PF-01367338) is an intravenous, potent, selective PARP-1 and 2 inhibitor (Ki = 1.4 nM). In pre… Expand
Is this relevant?
2011
2011
e13552 Background: Within the past several years multiple PARP inhibitors have been entered into clinical trials, in a variety of… Expand
Is this relevant?
2011
2011
e13615 Background: PF-01367338 is a poly (ADP-ribose) polymerase (PARP) inhibitor. The phosphate salt of PF-01367338 (PF-01367338… Expand
Is this relevant?
2011
2011
TPS130 Background: TNBC patients who do not achieve pathologic complete response (pCR) have an extremely high risk of disease… Expand
Is this relevant?
2011
2011
Background Based on recently reported I-SPY trial, TNBC patients who had residual disease category II or III had 2-year disease… Expand
Is this relevant?
2011
2011
3054 Background: PARP activity in PBLs or PBMs, measured as poly(ADP-ribose) (PAR) levels, has been used as a biomarker in the… Expand
Is this relevant?